Trial Profile

Study of PD32766 for the diagnosis and potential treatment of CAIX-expressing solid tumors

Status: Planning

Phase of Trial: Phase 0

Latest Information Update: 22 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PD-32766 (Primary)
Indications Renal cell carcinoma; Solid tumours
Focus Diagnostic use; First in man

Most Recent Events

22 Dec 2023 New trial record
27 Nov 2023 According to a PeptiDream media release, this study scheduled to start in 2024.
27 Nov 2023 According to a PeptiDream media release, the company announced a collaboration with the National Cancer Center Japan to support development of a radiopharmaceutical program targeting carbonic anhydrase IX (CAIX) for the diagnosis and potential treatment of CAIX-expressing solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com